A Comparison of Two Initial Dosing Formulas
Primary Purpose
Diabetes Mellitus, Type 2
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Insulin detemir
Sponsored by

About this trial
This is an interventional treatment trial for Diabetes Mellitus, Type 2 focused on measuring basal insulin, hypoglycemia, diabetes mellitus type two
Eligibility Criteria
Inclusion Criteria:
- Type 2 diabetes
- Age 18 years and above
- Concurrently on ± sulfonylureas ± thiazolidinedione ± DDP IV inhibitors ± metformin ± glinides
- A1c ≥ 7.0% but ≤ 10%
- Capable of self monitoring glucose ≥4/day
- Previously compliant with clinical recommendations
- Fasting blood glucose ≥ 150 mg/dl
- BMI ≤ 45 kg/m2
Exclusion Criteria:
- Urinary ketosis
- Currently or expected alteration in insulin sensitivity such as major surgery, infection, renal failure (creatinine >1.5 mg/dl), glucocorticoid treatment, recent (within 2 weeks) serious hypoglycaemic episode (requires assistant of another)
- Currently participating in another clinical trial
- Known or suspected allergy to insulin determir
- Using insulin
- Pregnancy or nursing or the intention of becoming pregnant or not using adequate
- Significant liver or heart failure.
Sites / Locations
- Diabetes Care Center
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
Insulin determir
Arm Description
Outcomes
Primary Outcome Measures
Days to reach the titration target
The number of days for the subject to reach the titration target blood sugar of 110 ml/dl
Secondary Outcome Measures
The frequency of reported and documented (<70 mg/dl) hypoglycemic events per 24 hour period
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01377155
Brief Title
A Comparison of Two Initial Dosing Formulas
Official Title
A Comparison of Two Initial Dosing Formulas for Basal Insulin in Type 2 Diabetes Mellitus
Study Type
Interventional
2. Study Status
Record Verification Date
August 2013
Overall Recruitment Status
Completed
Study Start Date
June 2011 (undefined)
Primary Completion Date
December 2011 (Actual)
Study Completion Date
December 2011 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Diabetes Care Center
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study will evaluate two methods of starting basal insulin to see which method may achieve a faster-to-goal titration.
Detailed Description
The current recommended starting dose of basal insulin in type 2 diabetes is either a fixed dose, e.g. 10 U, or a weight-based formulas, 0.1-0.2 U/kg. The estimate of eventual titration dose to attempt to reach a fasting glucose goal is 0.49 U/kg. Those many weeks of dosage upward titration are required. The investigators propose to compare the current recommended weight based, 0.1 U/kg to a correction factor derived formula. Starting with an insulin tolerance test estimation of basal dose, one would arrive at the eventual titrated basal insulin dose in significantly less days than starting at a starting dose estimate of 0.1 U/kg. Further, there would be no significant increase in overall reported hypoglycemia.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2
Keywords
basal insulin, hypoglycemia, diabetes mellitus type two
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
20 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Insulin determir
Arm Type
Other
Intervention Type
Drug
Intervention Name(s)
Insulin detemir
Intervention Description
Subjects will be randomized to weight based method of 0.1 U/kg for basal insulin or a starting dose based upon an insulin challenge. Subject will record morning fasting blood sugar daily. Using a three day average, the subject will titrate the dose of basal insulin either increasing or lowering by three units based upon target blood glucose of 110 mg/dl.
Primary Outcome Measure Information:
Title
Days to reach the titration target
Description
The number of days for the subject to reach the titration target blood sugar of 110 ml/dl
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
The frequency of reported and documented (<70 mg/dl) hypoglycemic events per 24 hour period
Time Frame
12 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Type 2 diabetes
Age 18 years and above
Concurrently on ± sulfonylureas ± thiazolidinedione ± DDP IV inhibitors ± metformin ± glinides
A1c ≥ 7.0% but ≤ 10%
Capable of self monitoring glucose ≥4/day
Previously compliant with clinical recommendations
Fasting blood glucose ≥ 150 mg/dl
BMI ≤ 45 kg/m2
Exclusion Criteria:
Urinary ketosis
Currently or expected alteration in insulin sensitivity such as major surgery, infection, renal failure (creatinine >1.5 mg/dl), glucocorticoid treatment, recent (within 2 weeks) serious hypoglycaemic episode (requires assistant of another)
Currently participating in another clinical trial
Known or suspected allergy to insulin determir
Using insulin
Pregnancy or nursing or the intention of becoming pregnant or not using adequate
Significant liver or heart failure.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Allen B King, MD
Organizational Affiliation
Diabetes Care Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Diabetes Care Center
City
Salinas
State/Province
California
ZIP/Postal Code
93901
Country
United States
12. IPD Sharing Statement
Learn more about this trial
A Comparison of Two Initial Dosing Formulas
We'll reach out to this number within 24 hrs